Status:
COMPLETED
Randomized Therapy In Status Epilepticus
Lead Sponsor:
Marinus Pharmaceuticals
Conditions:
Status Epilepticus
Eligibility:
All Genders
12+ years
Phase:
PHASE3
Brief Summary
This study evaluated the effectiveness and safety of an investigational product (IP), intravenous (IV) ganaxolone, to treat participants with status epilepticus (SE).
Detailed Description
This is a double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of IV ganaxolone in status epilepticus. Investigational product was added to standard of care following...
Eligibility Criteria
Inclusion
- Participant, participant's parent, guardian, or legal authorized representative (LAR) must provide signed of informed consent/assent, and once capable (per institution guidelines), there must be documentation of consent/assent by the participant demonstrating they are willing and aware of the investigational nature of the study and related procedures. Where allowed by law, where the participant lacks the capacity to make informed decisions regarding his/her medical treatment options, the treating clinician may follow their deferred consenting practices. The clinician will make the final decision based on the best interests of the particiapant.
- Male or females 12 years of age and older at the time of the first dose of IP
- SE meeting the following criteria:
- a. A diagnosis of SE with or without prominent motor features based on clinical and EEG findings:
- i. Diagnosis is established by:
- For SE with prominent motor features: Clinical and EEG seizure activity indicative of convulsive, myoclonic or focal motor SE.
- For SE without prominent motor features (nonconvulsive SE): Appropriate clinical features and an EEG indicative of non-convulsive status epilepticus (NCSE)
- ii. For any type of SE:
- At least 6 minutes of cumulative seizure activity over a 30-minute period within the hour before IP initiation, AND
- Seizure activity during the 30 minutes immediately prior to IP initiation
- b. The treating clinician(s) anticipate that IV anesthesia is likely to be the next treatment for SE that persists following initiation of IP
- Participants must have received any two or more of the following agents for treatment of the current episode of SE administered at an adequate dose and for a sufficient duration, in the judgment of the investigator, to demonstrate efficacy
- Benzodiazepines,
- IV Fosphenytoin/phenytoin,
- IV Valproic acid,
- IV Levetiracetam,
- IV Lacosamide,
- IV Brivaracetam, or
- IV Phenobarbital
- Body mass index (BMI) \< 40 or, if BMI is not able to be calculated at screening, participant is assessed by investigator as not morbidly obese
Exclusion
- Life expectancy of less than 24 hours
- Anoxic brain injury or an uncorrected rapidly reversable metabolic condition as the primary cause of SE (e.g., hypoglycemia \< 50 milligram per deciliter \[mg/dL\] or hyperglycemia \> 400 mg/dL)
- Participants who have received high-dose IV anesthetics (e.g., midazolam, propofol, thiopental, or pentobarbital) during the current episode of SE for more than 18 hours, or who continue to have clinical or electrographic evidence of persistent seizures while receiving high-dose IV anesthetics.
- Clinical condition or advance directive that would NOT permit use of IV anesthesia
- Participants known or suspected to be pregnant
- Participants with known allergy or sensitivity to progesterone or allopregnanolone medications/supplements
- Receiving a concomitant IV product containing Captisol®
- Known or suspected hepatic insufficiency or hepatic failure leading to impaired synthetic liver function.
- Known or suspected stage 3B (moderate to severe; estimated glomerular filtration rate \[eGFR\] 44-30 milliliter/minutes/1.73-meter square \[mL/min/1.73m\^2\]), stage 4 (severe; eGFR 29-15 mL/min/1.73m\^2), or stage 5 (kidney failure; eGFR \< 15 mL/min/1.73m\^2 or dialysis) kidney disease
- Use of an investigational product for which less than 30 days or 5 half-lives have elapsed from the final product administration. Participation in a non-interventional clinical study does not exclude eligibility.
Key Trial Info
Start Date :
December 9 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 28 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04391569
Start Date
December 9 2020
End Date
April 28 2024
Last Update
May 29 2025
Active Locations (74)
Enter a location and click search to find clinical trials sorted by distance.
1
Marinus Research Site
Birmingham, Alabama, United States, 35233
2
Marinus Research Site
Phoenix, Arizona, United States, 85013
3
Marinus Research Site
Little Rock, Arkansas, United States, 72205
4
Marinus Research Site
Downey, California, United States, 90242